SCHEMBL26032063

SCHEMBL26032063

CCCC(=O)NCCOCCC(=O)NCCOCCC(=O)NCCOCCOCCOCCOCCN(CCOCCOCCOCCOCCNC(=O)CCOCCNC(=O)CCOCCNC(=O)CCC)C(=O)CCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC9A3 P48764 6/20 0.33
DRD2 P14416 1/20 0.31
POLB P06746 1/20 0.30
HSD17B10 Q99714 1/20 0.30
HDAC3 O15379 1/20 0.30
HDAC4 P56524 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC7 Q8WUI4 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC10 Q969S8 1/20 0.30
HDAC11 Q96DB2 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
HDAC9 Q9UKV0 1/20 0.30
HDAC5 Q9UQL6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26032030 0.93 HPGD (0.40) HPGDHTTSMN1; SMN2DRD2HDAC3
SCHEMBL26032028 0.93 HPGD (0.40) HPGDHTTSMN1; SMN2DRD2HDAC3
SCHEMBL27306806 0.84 SMN1; SMN2 (0.37) HPGDHTTSMN1; SMN2SLC9A3POLB
SCHEMBL15627255 0.84 SMN1; SMN2 (0.37) HPGDHTTSMN1; SMN2SLC9A3POLB
SCHEMBL24136296 0.84 SMN1; SMN2 (0.37) HPGDHTTSMN1; SMN2SLC9A3POLB
SCHEMBL16118174 0.83 SMN1; SMN2 (0.38) HPGDHTTSMN1; SMN2POLBHSD17B10
SCHEMBL26032226 0.83 HPGD (0.43) HPGDHTTSMN1; SMN2POLBHSD17B10
SCHEMBL24136297 0.82 SMN1; SMN2 (0.47) HPGDHTTSMN1; SMN2DRD2POLB
SCHEMBL22134362 0.81 SMN1; SMN2 (0.37) HPGDHTTSMN1; SMN2SLC9A3DRD2
SCHEMBL14750406 0.81 SMN1; SMN2 (0.39) HPGDHTTSMN1; SMN2POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 HPGD 3988/4885HTT 4208/4885SMN1; SMN2 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.